Evidence map›Paper›PMID 37268719›Full record

ReviewNature reviews. Clinical oncology2023

Circulating tumour cells for early detection of clinically relevant cancer.

Rachel Lawrence, Melissa Watters, Caitlin R Davies, Klaus Pantel, Yong-Jie Lu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 171 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
171citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

171 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. [Liquid Biopsy Revolutionizes the Precise Management of Tumors Across the Entire Course: Current Situation and Future Prospects].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Evaluating the prognostic impact of multipleEuropean journal of nuclear medicine and molecular imaging · 2026
    Trial
  8. Trial
  9. Trial
  10. Liquid biopsy in modern medicine: advancing diagnostics from molecular insights to clinical practice.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

111 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rachel LawrenceCentre for Biomarkers and Therapeutics, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-1023-5220
Melissa WattersBarts and London School of Medicine and Dentistry, Queen Mary University London, London, UK.
Caitlin R DaviesCentre for Biomarkers and Therapeutics, Barts Cancer Institute, Queen Mary University of London, London, UK.
Klaus Pantel *Department of Tumour Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. pantel@uke.de.ORCID 0000-0001-5736-2772
Yong-Jie Lu *Centre for Biomarkers and Therapeutics, Barts Cancer Institute, Queen Mary University of London, London, UK. y.j.lu@qmul.ac.uk.ORCID 0000-0001-6174-6621

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Given that cancer mortality is usually a result of late diagnosis, efforts in the field of early detection are paramount to reducing cancer-related deaths and improving patient outcomes. Increasing evidence indicates that metastasis is an early event in patients with aggressive cancers, often occurring even before primary lesions are clinically detectable. Metastases are usually formed from cancer cells that spread to distant non-malignant tissues via the blood circulation, termed circulating tumour cells (CTCs). CTCs have been detected in patients with early stage cancers and, owing to their association with metastasis, might indicate the presence of aggressive disease, thus providing a possible means to expedite diagnosis and treatment initiation for such patients while avoiding overdiagnosis and overtreatment of those with slow-growing, indolent tumours. The utility of CTCs as an early diagnostic tool has been investigated, although further improvements in the efficiency of CTC detection are required. In this Perspective, we discuss the clinical significance of early haematogenous dissemination of cancer cells, the potential of CTCs to facilitate early detection of clinically relevant cancers, and the technological advances that might improve CTC capture and, thus, diagnostic performance in this setting.

Indexed as

NeoplasmsNeoplastic Cells, CirculatingHumans

Identifiers

PMID37268719
PMCPMC10237083

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.